Specialist/Senior Specialist, Clinical Budgets and Contracts

The role

This person will assist in the financial oversight of Axsome-sponsored clinical trials. They will lead CDA review and processing, develop and negotiate site budgets, and support site payments.

What you will do

• Lead the review and execution of CDAs and NMDAs for Clinical and liaise with Legal
• Develop clinical trial site budgets for assigned trials and incorporate feedback from the study team
• Negotiate clinical trial site budgets and payment terms for assigned trials
• Assist in building site organizations, contacts, site budgets, and payment terms in the site payment system
• Maintain a master site budget tracker for assigned trials
• Maintain accurate and up-to-date contract files, databases, and workflow trackers
• Monitor study CTA milestones and deadlines
• Facilitate QC review and execution of finalized clinical trial agreements
• Support the site payment process from study start-up through payment query resolution
• Support responses to queries in the Site Payments Inbox, accruals, expenses, payment reporting, and the Finance team audit process

Required qualifications

• Bachelor’s degree from an accredited college or university
• 1–3 years of experience in the pharmaceutical, biotechnology, or clinical research industry
• 1–2 years of direct budget negotiation experience
• Advanced proficiency in Excel and the ability to quickly manipulate and analyze large data sets and build reports
• Ability to work on site Monday, Tuesday, and Thursday
• Strong knowledge of clinical trials and Good Clinical Practice (GCP)
• Self-driven, with the ability to work independently and collaboratively in a fast-paced team environment
• Strong ability to adapt to changing priorities and deadlines

Nice to have

• Experience with project management tools such as Smartsheet
• Experience with data processing tools such as Power BI

Benefits

• Annual bonus
• Significant equity
• Generous benefits package

About the company

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. Their neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine.